Navigation Links
Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
Date:6/23/2008

not well tolerated by many Cystinosis patients, who experience severe gastrointestinal distress from the drug. Additionally, the strict, current four times daily dose regimen means that Cystinosis patients must be awakened every night to take the medicine. These side effects and frequent dosing requirements result in non-compliance or skipped doses for many patients. Studies have shown that non-compliance with the current cysteamine bitartrate dose regimen can lead to deteriorating kidney function and other complications.

Based on safety and efficacy studies performed at UCSD, Raptor believes that Cystinosis patients could benefit from a more convenient and superior treatment alternative utilizing DR Cysteamine.

Mr. Daley stated, "We are pleased to have been invited to present at the International Cystinosis Conference. I look forward to sharing results from studies performed at UCSD with a delayed-release form of cysteamine bitartrate which suggest that DR Cysteamine has the potential to become a safer and more effective treatment option for Cystinosis patients and could resolve current non-compliance issues prevalent in this patient population. These findings are supported by the Cystinosis Research Foundation's survey results on the challenges patients face in complying with the current drug's frequent dosing requirements, which I also plan to present. Our goal is to improve the quality of life of the Cystinosis patients and their families."

Raptor plans to initiate an expanded study of its final proprietary DR Cysteamine formulation in collaboration with the UCSD clinical researchers in 2009.

About Cystinosis Foundation Ireland and the International Cystinosis Conference

Cystinosis Foundation Ireland was set up in 2003 to support Cystinosis patients and their families. The goal of the Foundation is to raise awareness about Cystinosis and support research through its fundraising efforts. The International Cystinosis Conference
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
2. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
3. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
4. Raptor Pharmaceuticals Acquires Orphan Clinical Program
5. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
9. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
10. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
11. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... South Carolina (PRWEB) July 29, 2014 DisasterTalk ... teams of people where cell phone masts or other transmitters ... up to 100 feet away without the need for any ... target longer ranges. , The new app has launched as ... US homes are at very high risk of being affected ...
(Date:7/29/2014)... 2014 Quorum Review IRB, the ... awarded accreditation by the International Association of ... Six Sigma Deployment Program. The citation recognizes robust ... , Quorum’s Lean Six Sigma program was evaluated ... designation. The designation is a public statement of ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... Bryan, TX (PRWEB) July 29, 2014 ... of autonomous modular cleanrooms, today announced a new leadership ... in the United States and abroad. , Maik ... named as the company’s President charged with leading the ... , “As we enter this stage of development and ...
Breaking Biology Technology:DisasterTalk App Could Save Lives as Report Reveals 8% of US Homes at Very High Risk of Natural Disaster 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2
... Molecular Origami is ... help illustrate the basics of DNA origami, Harvard’s Wyss Institute has created a Flash-based interactive ... a DNA molecule and then allowing it to self assemble. , ... Boston, Mass. (PRWEB) January 28, 2010 -- Molecular ...
... world,s most powerful supercomputers, scientists at Lawrence Berkeley ... a good match for the future development of ... for green energy production because of their ability ... on "Franklin," a Cray XT4 massively parallel processing ...
... PRINCETON, N.J. , Jan. 27 Covance Inc. (NYSE: ... December 31, 2009 of $0.64 per diluted share.  For ... basis, inclusive of $0.10 per share in gains related to ... in the third quarter.  Excluding the gains on sales and the tax ...
Cached Biology Technology:Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Mismatched alloys are a good match for thermoelectrics 2Mismatched alloys are a good match for thermoelectrics 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:7/28/2014)... connections in prairie dogs have uncovered relationships that ... dog communities that may help limit the spread ... The work was done by researchers from North ... Center (NESCent). , "Prairie dogs are increasingly rare ... Jennifer Verdolin, lead author of a paper on ...
(Date:7/27/2014)... to date, researchers from the U.K. provide national, regional, ... virus (HCV). Findings published in Hepatology, a journal of ... indicate that genotype 1 is the most prevalent worldwide, ... reside in East Asia. Genotype 3, at just over ... by genotypes 2, 4, 6, and 5. , ...
(Date:7/27/2014)... scientists at Barts Cancer Institute have found that targeting ... significantly more effective, according to research published in ... Institute, part of Queen Mary University of London, have ... signals the body to repair itself after chemotherapy or ... the researchers removed FAK from blood vessels that grew ...
Breaking Biology News(10 mins):Social network research may boost prairie dog conservation efforts 2Hepatitis C virus genotype 1 is most prevalent worldwide 2New drug target can break down cancer's barrier against treatment 2
... (Cincinnati, OH) In a study published today in the ... an international team of researchers based in the U.S. and ... lethal, breath holding episodes associated with the neurological disease Rett ... that affects around 1 in 10,000 young girls. On October ...
... Institute in Boston have identified a new type of cell ... animal,s own cells from immune system attack. This ... drive lupus and other autoimmune diseases in which the immune ... The discovery, published in the September 16 issue of ...
... October 4, 2010 Onconova Therapeutics, Inc. announced ... regarding a Special Protocol Assessment (SPA) for the design ... 01910.Na) as monotherapy in patients with myelodysplastic syndromes (MDS), ... the bone marrow. The SPA provides FDA evaluation and ...
Cached Biology News:Research breakthrough hailed on the anniversary of gene discovery 2Discovery of a cell that suppresses the immune system 2Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... is ideal for high-fidelity amplification of ... as cloning and mutagenesis. High ... enzyme preparation containing recombinant DNA polymerase ... Site5' exonuclease) activity. Platinum Anti-Pfx ...
... PLAU N-term Antibody This antibody is generated ... synthetic peptide selected within aa 50~150 of ... in PBS with 0.09% (W/V) sodium azide. ... G column and eluted out with both ...
...
Biology Products: